Definitive Healthcare Corp. reports inducement grants under Nasdaq Listing Rule 5635(c)(4)
03 Novembro 2023 - 5:05PM
Definitive Healthcare (Nasdaq: DH), an industry leader in
healthcare commercial intelligence, today announced that in
connection with the hiring of Carrie Lazorchak as Definitive
Healthcare’s new Chief Revenue Officer, the Human Capital
Management and Compensation Committee (the “Committee”) of
Definitive Healthcare’s Board of Directors granted Ms. Lazorchak an
inducement award consisting of 385,695 time-based restricted stock
units (“RSUs”) effective November 1, 2023. This award was
individually negotiated and was granted as an inducement material
to Ms. Lazorchak’s commencement of employment with Definitive
Healthcare in accordance with Nasdaq Listing Rule 5635(c)(4).
The award is subject to the terms and conditions
of Definitive Healthcare’s 2023 Inducement Plan (the “Plan”) and
the terms and conditions of an applicable award agreement covering
the grant. The RSUs will vest as follows, subject to Ms.
Lazorchak’s continued employment through each such date: (i) 25%
will vest on the 1-year anniversary of the date of grant; (ii) the
remainder will vest in quarterly installments equal to 6.25% of the
total RSUs over the subsequent 3 years, until fully vested.
About Definitive Healthcare
At Definitive Healthcare, our passion is to
transform data, analytics, and expertise into healthcare commercial
intelligence. We help clients uncover the right markets,
opportunities, and people, so they can shape tomorrow’s healthcare
industry. Our SaaS platform creates new paths to commercial success
in the healthcare market, so companies can identify where to go
next. Learn more at definitivehc.com.
Investor Contact:Brian Denyeau ICR for
Definitive Healthcare brian.denyeau@icrinc.com 646-277-1251
Media Contact: Danielle Johns
djohns@definitivehc.com
Definitive Healthcare (NASDAQ:DH)
Gráfico Histórico do Ativo
De Mai 2024 até Jun 2024
Definitive Healthcare (NASDAQ:DH)
Gráfico Histórico do Ativo
De Jun 2023 até Jun 2024